Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells

Experimental and Molecular Medicine

Volumn 44, Issue 4, 2012, Pages 251-259

  Jang, Ji Young ^a   Kim, Min Kyoung ^a   Jeon, Yoon Kyung ^a   Joung, Yoon Ki ^b   Park, Ki Dong ^c   Kim, Chul Woo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Ajou University   (South Korea)

Author keywords

ABCG2 protein; Adenine nucleotide translocator 2; Combination; Drug therapy; Gene therapy; Human; Neoplastic stem cells; RNA; Small interfering

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENINE NUCLEOTIDE TRANSLOCASE SHORT HAIRPIN RNA; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA ACTIN; BREAST CANCER RESISTANCE PROTEIN; CD24 ANTIGEN; DOXORUBICIN; HERMES ANTIGEN; UNCLASSIFIED DRUG; UVOMORULIN;

ADENINE NUCLEOTIDE TRANSLOCATOR 2 GENE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL STRAIN MCF 7; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; ENZYME REPRESSION; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; VIRAL GENE THERAPY;

ADENOVIRIDAE;

EID: 84860529329     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2012.44.4.019     Document Type: Article

References (36)

1. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-7282
2. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006;25:2273-2284
3. Chevrollier A, Loiseau D, Chabi B, Renier G, Donay O, Malthiery Y, Stepien G. ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr 2005a;37:307-316
4. Chevrollier A, Loiseau D, Gautier F, Malthlery Y, Stepien G. ANT2 expression under hypoxic conditions produces opposite cell cycle behavior in 143B and HepG2 cancer cells. Mol Carcinog 2005b;42:1-8
5. Chevrollier A, Loiseau D, Stepien G. What is the specific role of ANT2 in cancer cells? Med Sci (Paris) 2005c;21:156-161
6. Chiodi I, Belgiovine C, Donà F, Scovassi I, Mondello C. Drug treatment of cancer cell lines: a way to select for cancer stem cells? Cancers 2011;3:1111-1128
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev 2005;5:275-284
8. Doerner A, Pauschinger M, Badorff A, Noutsias M, Giessn S, Schulze K, Bilger J, Rauch U, Schultheiss HP. Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans. FEBS Lett 1997;414: 258-262
9. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-45
10. Faure Vigny H, Heddi A, Giraud S, Chautard D, Stepien G. Expression of oxidative phosphorylation genens in renal tumors and tumoral cell lines. Mol Carcinog 1996;16:165-172
11. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003;106:8-16
12. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-1911
13. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1: 313-323
14. Jang JY, Choi Y, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 2008;10:R11
15. Jang JY, Jeon YK, Kim CW. Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 2010;10:391
16. Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelialto-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers 2011;3:716-729
17. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemair C, Kroemer G, Jacotot E, Brenner C. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 2006;66: 9143-9152
18. + cancer stem cells in glioblastoma. Mol Cancer 2006;5:67
19. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26;1357-1360
20. Luciakova K, Barath P, Poliakova D, Persson A, Nelson BD. Repression of the human adenine nucleotide translocase-2 gene in growth-arrested human diploid cells. J Biol Chem 2003;278:30624-30633
21. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133 HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-1758
22. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888
23. Pearce DJ, Bonnet D. The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopoietic stem cells. Exp Hematol 2007;35:1437-1446
24. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-1785
25. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65: 5506-5511
26. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29
27. Shen C, Buck AK, Liu X, Winkler M, Reske SN. Gene silencing by adenovirus delivered siRNA. FEBS Letters 2003;539:111-114
28. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59
29. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-273
30. Stepien G, Torroni A, Chung AB, Hodge JA, Wallace DC. Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation. J Biol Chem 1992;267:14592-14597
31. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001; 20:2122-2133
32. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME. Association of increased basement membrane invasive-ness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992;150:534-544
33. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema J P, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402
34. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008;15:947-958
35. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98:1166-1173
36. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-1034